The coordinated inhibition of HDAC6, HDAC3, and HDAC4 by BKS-112 may synergistically contribute to its potent anticancer effects, as these isoforms play distinct but complementary roles in cancer cell survival and progression. This evidence concerns the gene HDAC4 and cancer.